NVO

$38.43

Post-MarketAs of Mar 17, 8:00 PM UTC

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$38.43
Potential Upside
178.4%
Whystock Fair Value$106.99
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryDrug Manufacturers - General

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabet...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$171.38B
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
10.83
Beta
Defensive asset. Lower volatility than the S&P 500.
0.27
Div Yield
Strong income play. Yield provides a meaningful total return floor.
482.00%
ROIC
Elite ROE. Management converts capital into profit efficiently.
60.70%
Quick Ratio
Tight liquidity. Monitor cash flow carefully against debt.
0.54

Recent News

GuruFocus.com
Mar 17, 2026

HSBC Downgrades Eli Lilly, Cuts PT to $850, Flags Obesity Market Risks

Analysts say pricing pressure and competition could limit market growth to $80B--$120B, below consensus expectations above $150B.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Simply Wall St.
Mar 17, 2026

Novo Nordisk Telehealth Deal With Hims And Hers Puts GLP-1 Pricing In Focus

Novo Nordisk (CPSE:NOVO B) has entered a partnership with Hims & Hers to provide access to its FDA approved GLP-1 obesity and diabetes drugs, Ozempic and Wegovy, through telehealth channels. The agreement resolves a public legal dispute between the two companies and could influence how patients in the United States access branded GLP-1 treatments. The announcement comes at a time of increasing competition and the rise of copycat medications in the obesity treatment space. For investors...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Barrons.com
Mar 17, 2026

Eli Lilly Stock Gets Downgraded. It Faces Stiff Headwinds After Strong Run-Up.

Eli Lilly, the maker of Zepbound and Mounjaro, faces stiff price competition in the coming year, HSBC says.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Motley Fool
Mar 17, 2026

Why Eli Lilly Stock Just Dropped

Eli Lilly's stock price is based on growth rates that might fall short.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
24/7 Wall St.
Mar 17, 2026

Eli Lilly Falls 5% — FDA Oral Obesity Pill Decision and Novo Nordisk Rivalry Weigh on Shares

Eli Lilly (NYSE:LLY) stock is down 5% in Tuesday afternoon trading, with shares falling to $937 from a prior close of $989.12. The move adds to a rough stretch for the stock, which is now down 13% year to date from $1,072.90 at the start of 2026. The selloff reflects a convergence of pressures: mounting ... Eli Lilly Falls 5% — FDA Oral Obesity Pill Decision and Novo Nordisk Rivalry Weigh on Shares

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.